MAI Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,686
Closed -$267K – 2155
2026
Q2
$267K Buy
5,686
+5,583
+5,420% +$138K ﹤0.01% 1654
2026
Q1
$1.95K Buy
103
+44
+75% +$747 ﹤0.01% 3939
2025
Q4
$791 Buy
59
+49
+490% +$606 ﹤0.01% 3701
2025
Q3
$118 Hold
10
– – ﹤0.01% 3734
2025
Q2
$65 Hold
10
– – ﹤0.01% 3907
2025
Q1
$59 Hold
10
– – ﹤0.01% 3381
2024
Q4
$70 Buy
+10
New +$69 ﹤0.01% 3443
2022
Q2
– Sell
-880
Closed -$15K – 944
2022
Q1
$15K Hold
880
– – ﹤0.01% 897
2021
Q4
$18K Buy
+880
New +$28.1K ﹤0.01% 903

Other funds holding DFTX

MAI Capital Management's DFTX Position: Q3 2026 in Review

MAI Capital Management sold out of Definium Therapeutics (DFTX) in Q3 2026, closing a stake of 5,686 shares — an estimated $267K sold.

MAI Capital Management first reported a position in DFTX in Q4 2021 and held it in 9 quarters. The position peaked at $267K in Q2 2026. 349 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • MAI Capital Management reported no remaining Definium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • MAI Capital Management sold 5,686 Definium Therapeutics shares in Q3 2026, an estimated $267K.
  • MAI Capital Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 9 quarters.
  • MAI Capital Management's Definium Therapeutics position peaked at $267K in Q2 2026.
  • 349 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on MAI Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.